U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Central Admixture Pharmacy Services, Inc. - 498479 - 06/17/2020
  1. Warning Letters

CLOSEOUT LETTER

Central Admixture Pharmacy Services, Inc. MARCS-CMS 498479 —

Delivery Method:
Certified Email
Product:
Drugs
Recipient:
Recipient Name
Thomas J. Wilverding
Recipient Title
President
Central Admixture Pharmacy Services, Inc.

6580 Snowdrift Road
Suite 100
Allentown, PA 18106-9331
United States

Issuing Office:
Division of Pharmaceutical Quality Operations I

United States

(973) 331-4900

Dear Mr. Wilverding:

We are enclosing a copy of the Establishment Inspection Report (EIR) for the inspection conducted at your facility, Central Admixture Pharmacy Services, Inc., located at 6580 Snowdrift Road, Suite 100, Allentown, PA 18106-9331, from July 30, 2018, to August 22, 2018, by the U.S. Food and Drug Administration (FDA). We are also releasing a copy of the Establishment Inspection Report (EIR)s for the inspections conducted August 29, 2016, to September 19, 2016, February 3, 2015 to February 11, 2015, and June 4, 2014, to June 11, 2014.

When the Agency concludes that an inspection is “closed” under 21 C.F.R. 20.64(d)(3), it will release a copy of the EIR to the inspected establishment.

The Agency continually works to make its regulatory process and activities more transparent for regulated industry. Releasing this EIR to you is part of this effort. The copy being provided to you comprises the narrative portion of the report; it may reflect redactions made by the Agency in accordance with the Freedom of Information Act (FOIA) and 21 C.F.R. Part 20. This, however, does not preclude you from requesting and possibly obtaining any additional information under FOIA.

If there is any question about the released information, please contact Yvette Johnson, Compliance Officer at Yvette.Johnson@fda.hhs.gov.

Sincerely,
/S/
Stephanie Durso, Compliance Branch Director
Office of Pharmacy Quality Operations, Division I

Back to Top